Equillium (EQ) FCF Margin (2023 - 2024)
Equillium's (EQ) quarterly FCF Margin came in at 75.2% in Q4 2024, down 1333.0% year-on-year from 6.1% in Q1 2024, and down 19.44% on a QoQ basis from 62.96% in Q3 2024.
Equillium (EQ) FCF Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has 2 years of FCF Margin data on file, last reported at 75.2% in Q4 2024.
- On a quarterly basis, FCF Margin fell 1333.0% year-over-year to 75.2% in Q4 2024; TTM through Sep 2025 was 521.86%, a 47502.0% decrease from a year earlier, with the FY2024 full-year figure at 46.5%, up 1400.0% from the prior year.
- FCF Margin for Q4 2024 stood at 75.2%, down from 62.96% in the prior quarter.
- Over the last five years, FCF Margin for EQ reached as high as 4.82% in Q2 2024 and fell as low as 90.04% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Equillium | 242.14 Mn | 242.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -75.20% |
| Sep 30, 2024 | -62.96% |
| Jun 30, 2024 | 4.82% |
| Mar 31, 2024 | -82.51% |
| Dec 31, 2023 | -61.87% |
| Sep 30, 2023 | -21.52% |
| Jun 30, 2023 | -68.12% |
| Mar 31, 2023 | -90.04% |